Literature DB >> 27346347

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.

Matteo Forloni1, Romi Gupta1, Arvindhan Nagarajan1, Li-Sha Sun1, Yuying Dong1, Valentina Pirazzoli2, Maria Toki1, Anna Wurtz2, Mary Ann Melnick2, Susumu Kobayashi3, Robert J Homer4, David L Rimm5, Scott J Gettinger6, Katerina Politi5, Shaillay Kumar Dogra7, Narendra Wajapeyee8.   

Abstract

Oncogene-induced DNA methylation-mediated transcriptional silencing of tumor suppressors frequently occurs in cancer, but the mechanism and functional role of this silencing in oncogenesis are not fully understood. Here, we show that oncogenic epidermal growth factor receptor (EGFR) induces silencing of multiple unrelated tumor suppressors in lung adenocarcinomas and glioblastomas by inhibiting the DNA demethylase TET oncogene family member 1 (TET1) via the C/EBPα transcription factor. After oncogenic EGFR inhibition, TET1 binds to tumor suppressor promoters and induces their re-expression through active DNA demethylation. Ectopic expression of TET1 potently inhibits lung and glioblastoma tumor growth, and TET1 knockdown confers resistance to EGFR inhibitors in lung cancer cells. Lung cancer samples exhibited reduced TET1 expression or TET1 cytoplasmic localization in the majority of cases. Collectively, these results identify a conserved pathway of oncogenic EGFR-induced DNA methylation-mediated transcriptional silencing of tumor suppressors that may have therapeutic benefits for oncogenic EGFR-mediated lung cancers and glioblastomas.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27346347      PMCID: PMC4945411          DOI: 10.1016/j.celrep.2016.05.087

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  31 in total

Review 1.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

Review 2.  EGFR signaling and drug discovery.

Authors:  Georg Lurje; Heinz-Josef Lenz
Journal:  Oncology       Date:  2010-02-02       Impact factor: 2.935

3.  TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer.

Authors:  Hua-Lin Fu; Yue Ma; Lun-Gen Lu; Peng Hou; Bao-Jie Li; Wei-Lin Jin; Da-Xiang Cui
Journal:  J Biomed Nanotechnol       Date:  2014-07       Impact factor: 4.099

Review 4.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

5.  TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion.

Authors:  Hou-Gen Lu; Wang Zhan; Lin Yan; Rui-Ying Qin; Yi-Peng Yan; Zhen-Jiang Yang; Gui-Chao Liu; Gui-Qin Li; Hai-Feng Wang; Xing-Liang Li; Zhi Li; Lu Gao; Guo-Qing Chen
Journal:  Mol Med Rep       Date:  2014-08-26       Impact factor: 2.952

Review 6.  Oncogenic EGFR signaling networks in glioma.

Authors:  Paul H Huang; Alexander M Xu; Forest M White
Journal:  Sci Signal       Date:  2009-09-08       Impact factor: 8.192

7.  Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.

Authors:  Valentina Pirazzoli; Deborah Ayeni; Catherine B Meador; Basavaraju G Sanganahalli; Fahmeed Hyder; Elisa de Stanchina; Sarah B Goldberg; William Pao; Katerina Politi
Journal:  Clin Cancer Res       Date:  2015-09-04       Impact factor: 12.531

8.  Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer.

Authors:  Liu Yang; San-Jian Yu; Qi Hong; Yu Yang; Zhi-Ming Shao
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

9.  Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression.

Authors:  Rajendra Kumar Palakurthy; Narendra Wajapeyee; Manas K Santra; Claude Gazin; Ling Lin; Stephane Gobeil; Michael R Green
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

10.  A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype.

Authors:  Ryan W Serra; Minggang Fang; Sung Mi Park; Lloyd Hutchinson; Michael R Green
Journal:  Elife       Date:  2014-03-12       Impact factor: 8.140

View more
  21 in total

1.  Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.

Authors:  J-I Lai; Y-C Lai; Y-C Chen; N-K Wang; J-N Pan; W-S Wang; S-C Chang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

2.  p53-Suppressed Oncogene TET1 Prevents Cellular Aging in Lung Cancer.

Authors:  Piotr T Filipczak; Shuguang Leng; Carmen S Tellez; Kieu C Do; Marcie J Grimes; Cynthia L Thomas; Stephanie R Walton-Filipczak; Maria A Picchi; Steven A Belinsky
Journal:  Cancer Res       Date:  2019-01-08       Impact factor: 12.701

Review 3.  Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies.

Authors:  Narendra Wajapeyee; Romi Gupta
Journal:  Cancer Res       Date:  2021-09-16       Impact factor: 12.701

Review 4.  Mechanisms that regulate the activities of TET proteins.

Authors:  Kanak Joshi; Shanhui Liu; Peter Breslin S J; Jiwang Zhang
Journal:  Cell Mol Life Sci       Date:  2022-06-15       Impact factor: 9.207

5.  Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET.

Authors:  Arpita S Pal; Alejandra Agredo; Nadia A Lanman; Jihye Son; Ikjot Singh Sohal; Manvir Bains; Chennan Li; Jenna Clingerman; Kayla Gates; Andrea L Kasinski
Journal:  Cancer Res       Date:  2022-04-15       Impact factor: 13.312

Review 6.  Epigenetic dynamics in cancer stem cell dormancy.

Authors:  Alejandra I Ferrer; Jonathan R Trinidad; Oleta Sandiford; Jean-Pierre Etchegaray; Pranela Rameshwar
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 7.  Paradoxical roles of dual oxidases in cancer biology.

Authors:  Andrew C Little; Arvis Sulovari; Karamatullah Danyal; David E Heppner; David J Seward; Albert van der Vliet
Journal:  Free Radic Biol Med       Date:  2017-05-31       Impact factor: 7.376

8.  TET1 deficiency attenuates the DNA damage response and promotes resistance to DNA damaging agents.

Authors:  Jonathan B Coulter; Hernando Lopez-Bertoni; Katherine J Kuhns; Richard S Lee; John Laterra; Joseph P Bressler
Journal:  Epigenetics       Date:  2017-11-27       Impact factor: 4.528

9.  HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.

Authors:  Jiahui An; Jie Xu; Jiao Li; Song Jia; Xiaonan Li; Yanan Lu; Yuxin Yang; Zhuojia Lin; Xiaoru Xin; Mengying Wu; Qidi Zheng; Hu Pu; Xin Gui; Tianming Li; Dongdong Lu
Journal:  Oncotarget       Date:  2017-07-25

10.  Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.

Authors:  R Gupta; Q Yang; S K Dogra; N Wajapeyee
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.